相似文献
1
The pathology of multiple sclerosis and its evolution.
Philos Trans R Soc Lond B Biol Sci. 1999 Oct 29;354(1390):1635-40. doi: 10.1098/rstb.1999.0508.
2
Beta 2-adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis.
Trends Pharmacol Sci. 2004 Feb;25(2):67-71. doi: 10.1016/j.tips.2003.12.002.
3
[Pathogenesis of multiple sclerosis and other neural autoimmune diseases].
Verh Dtsch Ges Pathol. 1996;80:109-15.
4
Mechanisms of demyelination and tissue damage in multiple sclerosis.
Acta Neurol Belg. 1999 Mar;99(1):6-10.
5
The pathology of MS: new insights and potential clinical applications.
Neurologist. 2007 Mar;13(2):45-56. doi: 10.1097/01.nrl.0000253065.31662.37.
6
Multiple sclerosis: lessons from neuropathology.
Semin Neurol. 1998;18(3):337-49. doi: 10.1055/s-2008-1040885.
7
Multiple sclerosis: a battle between destruction and repair.
J Neurochem. 2007 Jan;100(2):295-306. doi: 10.1111/j.1471-4159.2006.04232.x. Epub 2006 Nov 13.
8
Influence of neurosteroids on the pathogenesis of multiple sclerosis.
Med Hypotheses. 2010 Aug;75(2):229-34. doi: 10.1016/j.mehy.2010.02.028. Epub 2010 Mar 12.
9
Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice.
Microsc Res Tech. 2001 Mar 15;52(6):731-9. doi: 10.1002/jemt.1057.
10
[A critical review of the current pathogenesis of multiple sclerosis and possible future trends].
Rev Neurol. 1999;28(9):909-15.
引用本文的文献
1
Ghrelin Attenuates Neuroinflammation and Demyelination in Experimental Autoimmune Encephalomyelitis Involving NLRP3 Inflammasome Signaling Pathway and Pyroptosis.
Front Pharmacol. 2019 Nov 6;10:1320. doi: 10.3389/fphar.2019.01320. eCollection 2019.
2
Performance and Capacity Measurement of the Lower Extremities in Multiple Sclerosis -How to Approach?
Noro Psikiyatr Ars. 2018;55(Suppl 1):S84-S87. doi: 10.29399/npa.23352.
3
Acute and Chronic Effects of Whole-Body Vibration on Balance, Postural Stability, and Mobility in Women With Multiple Sclerosis.
Dose Response. 2018 Dec 27;16(4):1559325818816577. doi: 10.1177/1559325818816577. eCollection 2018 Oct-Dec.
4
A Radiodensity Histogram Study of the Brain in Multiple Sclerosis.
Tomography. 2018 Dec;4(4):194-203. doi: 10.18383/j.tom.2018.00050.
5
Emerging Cellular and Molecular Strategies for Enhancing Central Nervous System (CNS) Remyelination.
Brain Sci. 2018 Jun 15;8(6):111. doi: 10.3390/brainsci8060111.
6
Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation.
J Neuroinflammation. 2018 Apr 24;15(1):121. doi: 10.1186/s12974-018-1164-y.
7
Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches.
Biomed Res Int. 2016;2016:4570351. doi: 10.1155/2016/4570351. Epub 2016 Dec 19.
8
Coactivation of Lower Limb Muscles during Gait in Patients with Multiple Sclerosis.
PLoS One. 2016 Jun 23;11(6):e0158267. doi: 10.1371/journal.pone.0158267. eCollection 2016.
9
Dynamometer-based measure of spasticity confirms limited association between plantarflexor spasticity and walking function in persons with multiple sclerosis.
J Rehabil Res Dev. 2014;51(6):975-84. doi: 10.1682/JRRD.2013.08.0186.
10
Multiple sclerosis: overview of disease-modifying agents.
Perspect Medicin Chem. 2014 Oct 5;6:65-72. doi: 10.4137/PMC.S13213. eCollection 2014.
本文引用的文献
1
Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients.
J Clin Invest. 1999 Mar;103(6):807-15. doi: 10.1172/JCI5150.
2
Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1.
Eur J Immunol. 1999 Feb;29(2):626-32. doi: 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.0.CO;2-A.
3
Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?
J Exp Med. 1999 Mar 1;189(5):865-70. doi: 10.1084/jem.189.5.865.
4
Identification of autoantibodies associated with myelin damage in multiple sclerosis.
Nat Med. 1999 Feb;5(2):170-5. doi: 10.1038/5532.
5
Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology.
Brain Pathol. 1998 Oct;8(4):681-94. doi: 10.1111/j.1750-3639.1998.tb00194.x.
6
MHC haplotype-dependent regulation of MOG-induced EAE in rats.
J Clin Invest. 1998 Sep 15;102(6):1265-73. doi: 10.1172/JCI3022.
7
Axonal transection in the lesions of multiple sclerosis.
N Engl J Med. 1998 Jan 29;338(5):278-85. doi: 10.1056/NEJM199801293380502.
8
The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion.
Brain. 1997 Aug;120 ( Pt 8):1461-83. doi: 10.1093/brain/120.8.1461.
9
Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis.
Ann Neurol. 1997 Jul;42(1):74-84. doi: 10.1002/ana.410420113.
10
Axonal damage in acute multiple sclerosis lesions.
Brain. 1997 Mar;120 ( Pt 3):393-9. doi: 10.1093/brain/120.3.393.
Zotero 插件